Novo Nordisk delivered robust financial results for the first nine months of 2024, with sales increasing 24% at CER to DKK 204.7 billion and operating profit growing 22% at CER to DKK 91.6 billion. The growth was primarily driven by GLP-1 diabetes sales rising 26% and Obesity care surging 44% to DKK 43.7 billion.The company achieved significant R&D milestones, including successful completion of the SOUL cardiovascular outcomes trial with oral semaglutide and positive ESSENCE trial results for semaglutide 2.4mg in MASH treatment. The phase 2a trial with monlunabant in obesity was completed, with plans to initiate a larger phase 2b trial in 2025.For 2024, Novo Nordisk has updated its outlook, now expecting sales growth of 23-27% at CER and operating profit growth of 21-27% at CER. The guidance reflects continued investments in supply chain expansion and R&D, while accounting for periodic supply constraints across products due to high demand. The company has increased its presence in obesity treatment markets and strengthened its diabetes care leadership with a 33.9% global value market share.

Novo Nordisk delivered robust financial results for the first nine months of 2024, with sales increasing 24% at CER to DKK 204.7 billion and operating profit growing 22% at CER to DKK 91.6 billion. The growth was primarily driven by GLP-1 diabetes sales rising 26% and Obesity care surging 44% to DKK 43.7 billion.The company achieved significant R&D milestones, including successful completion of the SOUL cardiovascular outcomes trial with oral semaglutide and positive ESSENCE trial results for semaglutide 2.4mg in MASH treatment. The phase 2a trial with monlunabant in obesity was completed, with plans to initiate a larger phase 2b trial in 2025.For 2024, Novo Nordisk has updated its outlook, now expecting sales growth of 23-27% at CER and operating profit growth of 21-27% at CER. The guidance reflects continued investments in supply chain expansion and R&D, while accounting for periodic supply constraints across products due to high demand. The company has increased its presence in obesity treatment markets and strengthened its diabetes care leadership with a 33.9% global value market share.